GLP-1 and CGM Convergence Market Size Worth USD 4.47 Billion by 2034 | CAGR: 11.7%

The GLP-1 and CGM convergence market size is expected to reach USD 4.47 billion by 2034, according to a new study by Polaris Market Research. The report “GLP-1 and CGM Convergence Market Size, Share, Trends, & Industry Analysis Report: By GLP-1 Therapy Type, By CGM Device Type, By Patient Population, By Payment Pathway, and By Region; Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Demand is building around one practical question: how is a patient's glucose responding to GLP-1 treatment. Continuous glucose monitoring (CGM) sensors give care teams a day-by-day answer, which is bringing drug makers, sensor makers and digital health firms closer together. Rising type 2 diabetes and obesity rates are widening the pool of people who could use both.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: GLP-1 and CGM Convergence Market Report

Access is shaping growth as much as clinical need. Lower GLP-1 prices and wider payer attention to glucose monitoring are bringing more people into treatment, and every new GLP-1 user is a possible CGM user. Over-the-counter sensors are also letting people start tracking without a prescription.

Drug makers and device makers still sell separately, so partnerships and data links are the main route to a joined-up offer. Coverage gaps and unclear reimbursement are the main brake on adoption, and upcoming Medicare decisions will set how fast it moves.

Top of FormGLP-1 and CGM Convergence Market Report Highlights

• Injectable GLP-1 and dual agonists held 71.35% of the market in 2025, as oral options have only recently reached patients.

• Over-the-counter biowearable CGM is the fastest growing device segment, projected to grow at a 18.94% CAGR from 2026 to 2034, as sensors become available without a prescription.

• North America led the market in 2025 with a 68.42% share, as the US is the most developed market for both GLP-1 drugs and CGM.

• Asia Pacific is the fastest growing region, with a projected 15.42% CAGR from 2026 to 2034, as diabetes cases rise in China, India and Japan.

• Wider GLP-1 use at lower prices and the push for Medicare coverage of CGM in non-insulin type 2 diabetes are the main forces behind growth, while coverage gaps remain the main restraint.

• A few global key market players include Abbott Laboratories, DexCom, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, and Senseonics Holdings, Inc.

GLP-1 and CGM Convergence Market report on the basis of GLP-1 therapy, CGM device, patient population, payment pathway, and region:

By GLP-1 Therapy Outlook (Revenue, USD Billion, 2021-2034)

• Injectable GLP-1 and Dual Agonists
• Oral GLP-1
• Next Generation Multi Agonists

By CGM Device Outlook (Revenue, USD Billion, 2021–2034)

• Prescription Wearable CGM
• Over the Counter Biowearable CGM
• Implantable CGM

By Patient Population Outlook (Revenue, USD Billion, 2021–2034)

• Type 2 Diabetes on GLP-1
• Obesity or Overweight without Diabetes
• Prediabetes and Wellness

By Payment Pathway Outlook (Revenue, USD Billion, 2021–2034)

• Medicare and Medicaid
• Commercial Insurance
• Self Pay

By Regional Outlook (Revenue, USD Billion, 2021–2034)

• North America

• US
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Vietnam
• Australia
• Rest of Asia Pacific

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa